Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival

Timothy E. Richardson, Seema Patel, Jonathan Serrano, Adwait Amod Sathe, Elena V. Daoud, Dwight H Oliver, Elizabeth A Maher, Alejandra Madrigales, Bruce E Mickey, Timothy Taxter, George Jour, Charles L White, Jack M Raisanen, Chao Xing, Matija Snuderl, Kimmo J Hatanpaa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Glioblastoma (GBM), representing WHO grade IV astrocytoma, is a relatively common primary brain tumor in adults with an exceptionally dismal prognosis. With an incidence rate of over 10 000 cases in the United States annually, the median survival rate ranges from 10-15 months in IDH1/2-wildtype tumors and 24-31 months in IDH1/2-mutant tumors, with further variation depending on factors such as age, MGMT methylation status, and treatment regimen. We present a cohort of 4 patients, aged 37-60 at initial diagnosis, with IDH1-mutant GBMs that were associated with unusually long survival intervals after the initial diagnosis, currently ranging from 90 to 154 months (all still alive). We applied genome-wide profiling with a methylation array (Illumina EPIC Array 850k) and a next-generation sequencing panel to screen for genetic and epigenetic alterations in these tumors. All 4 tumors demonstrated methylation patterns and genomic alterations consistent with GBM. Three out of four cases showed focal amplification of the CCND2 gene or gain of the region on 12p that included CCND2, suggesting that this may be a favorable prognostic factor in GBM. As this study has a limited sample size, further evaluation of patients with similar favorable outcome is warranted to validate these findings.

Original languageEnglish (US)
Pages (from-to)501-507
Number of pages7
JournalJournal of neuropathology and experimental neurology
Volume78
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Glioblastoma
Genome
Methylation
Survival
Neoplasms
Gene Amplification
Epigenomics
Brain Neoplasms
Sample Size
Survival Rate
Incidence
Therapeutics

Keywords

  • Astrocytoma
  • Copy number analysis
  • Glioblastoma (GBM)
  • Long survival
  • Methylation array

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival. / Richardson, Timothy E.; Patel, Seema; Serrano, Jonathan; Sathe, Adwait Amod; Daoud, Elena V.; Oliver, Dwight H; Maher, Elizabeth A; Madrigales, Alejandra; Mickey, Bruce E; Taxter, Timothy; Jour, George; White, Charles L; Raisanen, Jack M; Xing, Chao; Snuderl, Matija; Hatanpaa, Kimmo J.

In: Journal of neuropathology and experimental neurology, Vol. 78, No. 6, 01.06.2019, p. 501-507.

Research output: Contribution to journalArticle

Richardson, Timothy E. ; Patel, Seema ; Serrano, Jonathan ; Sathe, Adwait Amod ; Daoud, Elena V. ; Oliver, Dwight H ; Maher, Elizabeth A ; Madrigales, Alejandra ; Mickey, Bruce E ; Taxter, Timothy ; Jour, George ; White, Charles L ; Raisanen, Jack M ; Xing, Chao ; Snuderl, Matija ; Hatanpaa, Kimmo J. / Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival. In: Journal of neuropathology and experimental neurology. 2019 ; Vol. 78, No. 6. pp. 501-507.
@article{28e017b1f35242bd8d8b5509104cd986,
title = "Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival",
abstract = "Glioblastoma (GBM), representing WHO grade IV astrocytoma, is a relatively common primary brain tumor in adults with an exceptionally dismal prognosis. With an incidence rate of over 10 000 cases in the United States annually, the median survival rate ranges from 10-15 months in IDH1/2-wildtype tumors and 24-31 months in IDH1/2-mutant tumors, with further variation depending on factors such as age, MGMT methylation status, and treatment regimen. We present a cohort of 4 patients, aged 37-60 at initial diagnosis, with IDH1-mutant GBMs that were associated with unusually long survival intervals after the initial diagnosis, currently ranging from 90 to 154 months (all still alive). We applied genome-wide profiling with a methylation array (Illumina EPIC Array 850k) and a next-generation sequencing panel to screen for genetic and epigenetic alterations in these tumors. All 4 tumors demonstrated methylation patterns and genomic alterations consistent with GBM. Three out of four cases showed focal amplification of the CCND2 gene or gain of the region on 12p that included CCND2, suggesting that this may be a favorable prognostic factor in GBM. As this study has a limited sample size, further evaluation of patients with similar favorable outcome is warranted to validate these findings.",
keywords = "Astrocytoma, Copy number analysis, Glioblastoma (GBM), Long survival, Methylation array",
author = "Richardson, {Timothy E.} and Seema Patel and Jonathan Serrano and Sathe, {Adwait Amod} and Daoud, {Elena V.} and Oliver, {Dwight H} and Maher, {Elizabeth A} and Alejandra Madrigales and Mickey, {Bruce E} and Timothy Taxter and George Jour and White, {Charles L} and Raisanen, {Jack M} and Chao Xing and Matija Snuderl and Hatanpaa, {Kimmo J}",
year = "2019",
month = "6",
day = "1",
doi = "10.1093/jnen/nlz025",
language = "English (US)",
volume = "78",
pages = "501--507",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival

AU - Richardson, Timothy E.

AU - Patel, Seema

AU - Serrano, Jonathan

AU - Sathe, Adwait Amod

AU - Daoud, Elena V.

AU - Oliver, Dwight H

AU - Maher, Elizabeth A

AU - Madrigales, Alejandra

AU - Mickey, Bruce E

AU - Taxter, Timothy

AU - Jour, George

AU - White, Charles L

AU - Raisanen, Jack M

AU - Xing, Chao

AU - Snuderl, Matija

AU - Hatanpaa, Kimmo J

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Glioblastoma (GBM), representing WHO grade IV astrocytoma, is a relatively common primary brain tumor in adults with an exceptionally dismal prognosis. With an incidence rate of over 10 000 cases in the United States annually, the median survival rate ranges from 10-15 months in IDH1/2-wildtype tumors and 24-31 months in IDH1/2-mutant tumors, with further variation depending on factors such as age, MGMT methylation status, and treatment regimen. We present a cohort of 4 patients, aged 37-60 at initial diagnosis, with IDH1-mutant GBMs that were associated with unusually long survival intervals after the initial diagnosis, currently ranging from 90 to 154 months (all still alive). We applied genome-wide profiling with a methylation array (Illumina EPIC Array 850k) and a next-generation sequencing panel to screen for genetic and epigenetic alterations in these tumors. All 4 tumors demonstrated methylation patterns and genomic alterations consistent with GBM. Three out of four cases showed focal amplification of the CCND2 gene or gain of the region on 12p that included CCND2, suggesting that this may be a favorable prognostic factor in GBM. As this study has a limited sample size, further evaluation of patients with similar favorable outcome is warranted to validate these findings.

AB - Glioblastoma (GBM), representing WHO grade IV astrocytoma, is a relatively common primary brain tumor in adults with an exceptionally dismal prognosis. With an incidence rate of over 10 000 cases in the United States annually, the median survival rate ranges from 10-15 months in IDH1/2-wildtype tumors and 24-31 months in IDH1/2-mutant tumors, with further variation depending on factors such as age, MGMT methylation status, and treatment regimen. We present a cohort of 4 patients, aged 37-60 at initial diagnosis, with IDH1-mutant GBMs that were associated with unusually long survival intervals after the initial diagnosis, currently ranging from 90 to 154 months (all still alive). We applied genome-wide profiling with a methylation array (Illumina EPIC Array 850k) and a next-generation sequencing panel to screen for genetic and epigenetic alterations in these tumors. All 4 tumors demonstrated methylation patterns and genomic alterations consistent with GBM. Three out of four cases showed focal amplification of the CCND2 gene or gain of the region on 12p that included CCND2, suggesting that this may be a favorable prognostic factor in GBM. As this study has a limited sample size, further evaluation of patients with similar favorable outcome is warranted to validate these findings.

KW - Astrocytoma

KW - Copy number analysis

KW - Glioblastoma (GBM)

KW - Long survival

KW - Methylation array

UR - http://www.scopus.com/inward/record.url?scp=85066351802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066351802&partnerID=8YFLogxK

U2 - 10.1093/jnen/nlz025

DO - 10.1093/jnen/nlz025

M3 - Article

C2 - 31034050

AN - SCOPUS:85066351802

VL - 78

SP - 501

EP - 507

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 6

ER -